Release 4

This page is part of the FHIR Specification (v4.0.1: R4 - Mixed Normative and STU) in it's permanent home (it will always be available at this URL). The current version which supercedes this version is 5.0.0. For a full list of available versions, see the Directory of published versions . Page versions: R4 R3

4.4.2.1070 HL7 v3 Value Set substanceAdminSubstitution

Vocabulary

Work Group

Maturity Level: N/A

External

Use Context: Any

This value set (http://terminology.hl7.org/ValueSet/v3-substanceAdminSubstitution) is defined as part of HL7 v3.

Summary

Defining URL:

http://terminology.hl7.org/ValueSet/v3-substanceAdminSubstitution

Version:

2018-08-12

Name:

v3.substanceAdminSubstitution

Title:

v3 Code System substanceAdminSubstitution

Definition:

Identifies what sort of change is permitted or has occurred between the therapy that was ordered and the therapy that was/will be provided.

OID:

(for OID based terminology systems)

Source Resource

XML / JSON

This value set is used in the following places:

CodeSystem: This value set is the designated 'entire code system' value set for v3.substanceAdminSubstitution

4.4.2.1070.1 Content Logical Definition

This value set includes codes from the following code systems:

Include all codes defined in http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution

4.4.2.1070.2 Expansion

This expansion generated 01 Nov 2019

This value set contains 9 concepts

Expansion based on http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution version 2018-08-12

All codes from system http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution

Lvl	Code	Display	Definition
0	_ActSubstanceAdminSubstitutionCode	ActSubstanceAdminSubstitutionCode	Description: Substitution occurred or is permitted with another product that may potentially have different ingredients, but having the same biological and therapeutic effects.
1	E	equivalent	Description: Substitution occurred or is permitted with another bioequivalent and therapeutically equivalent product.
2	EC	equivalent composition	Description: Substitution occurred or is permitted with another product that is a: pharmaceutical alternative containing the same active ingredient but is formulated with different salt, ester pharmaceutical equivalent that has the same active ingredient, strength, dosage form and route of administration Examples: Pharmaceutical alternative: Erythromycin Ethylsuccinate for Erythromycin Stearate Pharmaceutical equivalent: Lisonpril for Zestril
3	BC	brand composition	Description: Substitution occurred or is permitted between equivalent Brands but not Generics Examples: Zestril for Prinivil Coumadin for Jantoven
3	G	generic composition	Description: Substitution occurred or is permitted between equivalent Generics but not Brands Examples: Lisnopril (Lupin Corp) for Lisnopril (Wockhardt Corp)
2	TE	therapeutic alternative	Description: Substitution occurred or is permitted with another product having the same therapeutic objective and safety profile. Examples: ranitidine for Tagamet
3	TB	therapeutic brand	Description: Substitution occurred or is permitted between therapeutically equivalent Brands but not Generics > Examples: Zantac for Tagamet
3	TG	therapeutic generic	Description: Substitution occurred or is permitted between therapeutically equivalent Generics but not Brands > Examples: Ranitidine for cimetidine
1	F	formulary	Description: This substitution was performed or is permitted based on formulary guidelines.
1	N	none	No substitution occurred or is permitted.